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Summary Amatuximab is a chimeric monoclonal antibody
that targets mesothelin, which is expressed in virtually all
mesotheliomas and pancreatic adenocarcinomas. The ob-
jective of this study was to determine the dose-limiting
toxicity and the maximum tolerated dose. Patients with
mesothelioma, pancreatic adenocarcinoma or other
mesothelin-positive solid tumors were eligible for this
study. Amatuximab was administered weekly as an intra-
venous infusion in 4-week cycles at progressively increas-
ing doses ranging from 50 to 200 mg/m2. Seventeen pa-
tients received amatuximab. Two dose-limiting toxicities
were observed: one at 50 mg/m2 and one at 200 mg/m2; the
maximum tolerated dose of this study was determined to be
200 mg/m2. Of the 17 patients, 13 patients (76.5 %)
experienced treatment-related adverse events. The most
common adverse events were grade 1 fatigue (29.4 %)
and pyrexia (23.5 %). The maximum serum concentration
and area under the concentration curve values increased in
an almost dose-proportional manner. Three patients had
stable disease. Amatuximab was generally well tolerated
at doses up to 200 mg/m2. The pharmacokinetic profile of
amatuximab in the Japanese population was similar to that
seen in the United States population (Clinical Trials.gov
Identifier: NCT01018784).
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Introduction
Amatuximab (MORAb-009) is a high affinity, chimeric,
IgG1/κ monoclonal antibody targeting mesothelin, which is
a glycosyl-phosphatidyl inositol-linked membrane glycopro-
tein. The normal biological function of mesothelin is not
known. Mesothelin does not appear to be required for either
normal development or reproduction since there were no
apparent abnormalities in mesothelin knockout mice [1].
However, recent studies have shown that mesothelin binds
to the cell surface mucin, MUC16 (CA-125) [2–4], which is
commonly used as a marker to follow patients with ovarian
cancer. This interaction is thought to mediate cell adhesion,
suggesting a role in cancer metastasis. Mesothelin is highly
expressed in many common epithelial malignancies; however,
the expression in normal tissues is limited to mesothelial cells
lining the pleura, pericardium, and peritoneum [5]. Immuno-
histochemistry studies have shown that mesothelin is
expressed in virtually all mesotheliomas and pancreatic ductal
adenocarcinomas, a high percentage of epithelial ovarian can-
cers, and non-small cell carcinomas of the lung [6–10]. In
addition, mesothelin is expressed to varying degrees by other
tumors including endometrial adenocarcinoma, gastric adeno-
carcinoma, and cholangiocarcinoma [11].
In vitro, amatuximab elicits antibody-dependent cellular
cytotoxicity against mesothelin-expressing tumor cell lines
[12]. In vivo, tumor xenograft studies showed that
amatuximab plus chemotherapy led to a greater reduction in
the growth of mesothelin-expressing tumors than either
amatuximab or chemotherapy alone [12].
In the previous United States (US) phase I study, the single-
agent maximum tolerated dose (MTD) of amatuximab was
200 mg/m2. Two dose-limiting toxicities (DLTs) were noted at
the 400 mg/m2 dose level [13].
On the basis of these pre-clinical and clinical results, we
conducted a phase I study of amatuximab in Japanese patients
with solid tumors. The primary objective of this study was to
determine DLT and MTD in Japanese patients, and key sec-
ondary objectives were to examine the pharmacokinetics, anti-
amatuximab antibody formation (human anti-chimeric anti-
body: HACA), mesothelin expression, and preliminary anti-
tumor effect of amatuximab.
Materials and methods
Study design
This was a phase I dose-escalation study (MORAb-009-J081-
102 study) designed to determine DLT and MTD in Japanese
patients with solid tumors.
Amatuximab was administered weekly as an intravenous
infusion in 4-week cycles until disease progression or the
occurrence of a DLT. The first infusion was started at a rate
of 1 mg/min. If no allergic reactions occurred within 30 min,
the infusion rate could be increased up to a maximum rate of
5 mg/min. The second infusion could be started at the rate
tolerated in the prior infusion. Initially, prophylactic
premedication for allergic reactions was prohibited. During
the course of the study, the protocol was amended to require
premedication of antihistamines and acetaminophen prior to
all infusions. This occurred after the fourth patient was dosed
at 50 mg/m2.
In this study, the standard 3+3 dose escalation design was
used and intra-patient dose escalation was not allowed. The
starting dose of 50mg/m2 was chosen due to the occurrence of
a single DLT (deep venous thrombosis) in the US phase I
study at the 100 mg/m2 dose [13]. The protocol specified that
if a DLT occurred in the first three patients receiving either 50
or 100 mg/m2 dose, an additional three patients would be
treated at this same dose level. If no additional DLTs occurred,
then an escalation to the next dose could proceed. Six patients
were required at the 200 mg/m2 dose level even if no DLTs
were observed, as the dose was the MTD of the US phase I
study. The highest tolerated dose was defined as MTD of this
study. If two or more patients developed a DLT at a given
dose, the prior lower dose was declared as the MTD. The
following treatment-related toxicities that occurred in cycle 1
were defined as DLTs: any grade 4 hematologic toxicity
except for a grade 4 leukopenia or neutropenia (grade 4
leukopenia or neutropenia had to persist for longer than 7 days
to be defined as a DLT); any grade 3 or higher neutropenia
with fever of ≥38.0 °C; any grade 3 thrombocytopenia requir-
ing blood transfusion; any grade 3 gastrointestinal toxicities
(except for nausea, vomiting, or diarrhea that was controllable
by an antiemetic or antidiarrheal agent); and any grade 3 non-
hematologic toxicity with the exception of abnormal labora-
tory parameters not requiring treatment.
Patients and eligibility criteria
Japanese patients with histologically or cytologically diag-
nosed solid tumors not responsive to standard therapy or
lacking appropriate treatment options were eligible for this
study. In addition, the patients’ tumor was required to be
mesothelin positive as confirmed by immunohistochemistry
(IHC), except for patients with either a mesothelioma or a
pancreatic adenocarcinoma asmesothelin has been reported to
be expressed in virtually all of these types of tumors [6–8].
Other key inclusion criteria were as follows: age of 20–
79 years; a life expectancy of 12 weeks or more; Eastern
Cooperative Oncology Group performance score of 0 or 1;
adequate organ function [hemoglobin ≥9.0 g/dL; neutrophil
count ≥1.5×103/μL; white blood cell count 3.0–12.0×103/
μL; platelet count ≥10×104/μL; aspartate transaminase (AST)
≤5×upper limit of normal (ULN); alanine transaminase (ALT)
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≤5×ULN; alkaline phosphatase ≤5×ULN; total bilirubin
≤2.0 mg/dL; serum creatinine ≤2.0 mg/dL]. Patients were
excluded from the study if they met any of the following
criteria: having a brain metastasis presenting with clinical
symptoms or requiring medical treatment; being positive for
human immunodeficiency virus antibody, hepatitis C virus
antibody, or hepatitis B surface antigen; severe systemic in-
fection requiring treatment; history of hypersensitivity to pro-
tein formulation including monoclonal antibody, other active
malignancies; body cavity fluids (such as pleural effusion or
ascites) that could not be controlled by drainage.
Safety assessments
Adverse events (AEs) were graded based on the Common
Terminology Criteria for Adverse Events (CTCAE) v3.0, and
were coded based on Medical Dictionary for Regulatory Ac-
tivities v15.1.
Since amatuximab is a human-mouse chimeric monoclonal
antibody, there is a potential for immune mediated AEs (e.g.,
allergic reaction). These AEs were classified as adverse events
of interest (AEIs) based on the judgement by the investigators.
Antitumor activity
Tumor assessment was performed every two cycles by inves-
tigators according to Response Evaluation Criteria in Solid
Tumor v1.0 [14].
Pharmacokinetic assessments
During cycle 1, blood samples were collected on day 1 (within
1 h before the start of the amatuximab infusion; 0.5 h after the
start of the amatuximab infusion; at the end of the infusion;
0.5, 1, 2, and 4 h after the end of the amatuximab infusion; 24
and 72 h after the start of the amatuximab infusion); on day 8
and 15 (within 1 h before the start of the amatuximab infu-
sion); and on day 22 (within 1 h before the start of the
amatuximab infusion; 0.5 h after the start of the amatuximab
infusion; at the end of the infusion; 0.5, 1, 2, and 4 h after the
end of the amatuximab infusion; and 24 h after the start of the
amatuximab infusion). In all subsequent cycles, blood sam-
ples were collected on day 1 (within 1 h before the start of
amatuximab infusion) only. Serum amatuximab concentra-
tions were measured with an electrochemiluminescence im-
munoassay (ECLIA) which has a lower limit of quantification
of 0.098 μg/mL.
Serum concentrations of amatuximab were measured to
determine standard pharmacokinetic parameters including
maximum serum concentration (Cmax), area under the concen-
tration curve (AUC), time of maximum concentration (tmax),
and terminal half-life (t1/2). Pharmacokinetic parameters were
calculated by a noncompartmental approach usingWinNonlin
software v6.2 (Pharsight, Sunnyvale, CA).
Human anti-chimeric antibody assessments
In cycle 1, blood samples were collected on day 1 and day 15
(within 1 h before the start of the amatuximab infusion). In
cycle 2 and thereafter, blood samples were collected on day 1
(within 1 h before the start of amatuximab infusion). The
qualitative serum HACA level was measured with ECLIA.
Immunohistochemistry
Tumor tissue samples obtained from 53 patients were assayed
to investigate mesothelin expression by IHC using a commer-
cially available anti-mesothelin antibody, Novocastra Lyoph-
ilized Mouse Monoclonal Antibody Mesothelin (Leica
Biosystems, Newcastle, UK). Immunoreactive intensities
were graded as 0, no reaction; 1+, weak (i.e., stained light
brown with the thin rim along the cell membrane); 2+, mod-
erate (i.e., stained deep-brown with the thin rim along the cell
membrane); and 3+, strong (i.e., stained deep-brown with the
thick rim along the cell membrane or higher intensity). If any
immunohistochemical stains were observed in tumor tissue




Of 58 screened patients, 17 patients were enrolled between
November 2009 and March 2012 at Kinki University Faculty
of Medicine in Japan. The median age of the patients was
62 years (range, 56–79 years) (Table 1). The performance
status of all patients were 0 or 1. Of 17 patients, the most
common tumor types were colorectal cancer (seven patients)
and pancreatic adenocarcinoma (six patients).
Dose of amatuximab
All 17 patients were treated with amatuximab at one of the
dose levels from 50 mg/m2 to 200 mg/m2 according to the
dose escalation strategy (seven patients at 50 mg/m2, three
patients at 100 mg/m2, and seven patients at 200 mg/m2). Two
patients discontinued the study due to disease progression
before completion of cycle 1; these two patients were exclud-
ed from the DLT evaluation.
The median duration of amatuximab treatment was 30 days
(36 days at 50 mg/m2, 36 days at 100 mg/m2, and 29 days at
200 mg/m2).
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Safety
Of the 17 patients, 13 (76.5 %) experienced a treatment-
related AE. One patient at the 200 mg/m2 dose level died
due to a treatment-related AE (interstitial lung disease [ILD]).
The most common treatment-related AEs were fatigue (five
patients, 29.4 %), pyrexia (four patients, 23.5 %), and cyto-
kine release syndrome (three patients, 17.6 %) (Table 2). The
grade 3 or higher treatment-related AEs occurred in one
patient with a grade 3 cytokine release syndrome at the
50 mg/m2 dose level and one patient with a grade 5 ILD at
the 200 mg/m2 dose level; both were considered DLTs.
DLTs were evaluated in 15 patients who completed cycle 1.
At the initial dose level of 50 mg/m2, one of three patients
developed a DLT (a grade 3 cytokine release syndrome).
Since no additional DLTs occurred in the additional three
patients, the dose was escalated first to 100 mg/m2 and then
to 200 mg/m2. At the 200 mg/m2 dose level, one of the six
patients developed a DLT (a grade 5 ILD). A higher dose than
200 mg/m2 was not investigated in this study. As there was
only one patient with a DLT at each of the 50 and 200 mg/m2
dose levels, the MTD was determined to be 200 mg/m2
according to the definition of MTD in this study protocol.
Five of 17 patients (29.4 %) experienced AEIs (Table 3).
Common AEIs were cytokine release syndrome (three pa-
tients, 17.6 %), pyrexia (two patients, 11.8 %), and hot flush
(two patients, 11.8 %). The only grade 3 or higher AEI was a
grade 3 cytokine release syndrome (one patient, 5.9 %).
Pharmacokinetics and human anti-chimeric antibody
The serum concentration of amatuximab in cycle 1 is shown
in Fig. 1. Amatuximab exhibited a biphasic elimination pat-
tern. Pharmacokinetic parameters on day 1 and day 22 are
shown in Table 4. The mean Cmax on day 1 ranged from
33.2 μg/mL for the 50 mg/m2 dose to 133 μg/mL for the
200 mg/m2 dose, and the mean AUC(0-t) on day 1 ranged from
2380 to 10300 μg•h/mL. The mean t1/2, total clearance, and
Vss on day 1 were 92.3 to 108 h, 11.8 to 15.2 mL/h/m
2, and
1.77 to 2.06 L/m2, respectively. The mean Cmax on day 22
ranged from 40.4 μg/mL to 163 μg/mL, and the mean AUC(0-
t) and t1/2 values on day 22 ranged from 3210 to 15500 μg•h/
mL, and 101 to 154 h, respectively. These results reveal that
amatuximab has a low clearance as well as a low distribution
volume.
Table 1 Patient characteristics
Characteristic No. of patients
(n=17)
Age (years)




Body surface area (m2)
Median (Range) 1.64 (1.18–1.88)






Head and neck cancer 2
Mesothelioma 2
ECOG Eastern Cooperative Oncology Group
Table 2 Common treatment-related adverse events (≥10 % frequency)
Dose 50 mg/m2
(n=7)
100 mg/m2 (n=3) 200 mg/m2 (n=7) Total (n=17)
Grades 1 2 3 1 2 3 1 2 3 1 2 3 n (%)
Fatigue 3 0 0 1 0 0 1 0 0 5 0 0 5 (29.4)
Pyrexia 3 0 0 0 0 0 1 0 0 4 0 0 4 (23.5)
Cytokine release syndrome 0 1 1 0 0 0 0 1 0 0 2 1 3 (17.6)
AST increased 0 2 0 0 0 0 0 0 0 0 2 0 2 (11.8)
Decreased appetite 1 0 0 0 1 0 0 0 0 1 1 0 2 (11.8)
Hot flash 1 0 0 1 0 0 0 0 0 2 0 0 2 (11.8)
Nausea 1 0 0 0 0 0 1 0 0 2 0 0 2 (11.8)
Vomiting 2 0 0 0 0 0 0 0 0 2 0 0 2 (11.8)
Weight decreased 0 1 0 1 0 0 0 0 0 1 1 0 2 (11.8)
AST aspartate transaminase
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Eight of 17 patients (47.1 %) had at least 1 positive HACA
value during the study. Of these eight HACA-positive pa-
tients, one patient was positive for HACA expression prior
to receiving the amatuximab infusion and had increased titers
during the study. This patient experienced grade 3 cytokine
release syndrome and a high titer level of HACAwas found.
Five patients developed HACA during study treatment and
two patients developed HACA at the final sampling point
after finishing the study treatment. The occurrence of HACA
dropped to 30.8 % (four of 13 patients) when the protocol was
amended to mandate premedication with antihistamines and
acetaminophen prior to the amatuximab infusion. Five of 17
patients (29.4%) developed a positive HACAvalue in cycle 1.
A decrease in the serum concentration of amatuximab was
observed in three of these five patients (in the remaining two
patients, one had low titer levels of HACA and one
discontinued study treatment on day 14 due to progressive
disease) (Fig. 2). The three patients all experienced a grade 2
or 3 AEI, including grade 3 cytokine release syndrome.
Efficacy
Based on the investigator assessment, three of 17 patients
(17.6 %) had stable disease (SD) and 14 patients (82.4 %)
had progressive disease recorded as their best overall re-
sponse. The durations of SD for the three patients were 47+
(censored), 101, and 217 days.
Mesothelin immunohistochemistry
Tumor tissue samples from 53 patients were assayed for
mesothelin expression by IHC. Tissue samples from 46 pa-
tients with solid tumors other than mesothelioma and pancre-
atic adenocarcinoma were assayed for IHC prior to enrollment
because they were required by eligibility criteria to be
mesothelin positive. Eighteen of 46 patients were mesothelin
positive and nine patients were enrolled in this study. After
study completion, we assayed tissue samples obtained from
seven patients with mesothelioma and pancreatic adenocarci-
noma who provided informed consent for IHC as a biomarker
study. Of the seven patients, six patients enrolled were
mesothelin positive and one patient not enrolled was
mesothelin negative.
The results of mesothelin expression by IHC per tumor
type are presented in Table 5. Of 53 patients evaluable for
mesothelin expression, 24 patients (45.3 %) were positive for
mesothelin expression. Mesothelin expression were observed
in mesothelioma (two of two patients, 100.0 %), head and
neck cancer (two of two patients, 100.0 %), small intestine
cancer (one of one patient, 100.0 %), pancreatic adenocarci-
noma (four of five patients, 80.0 %), colorectal cancer (10 of
19 patients, 52.6 %), and biliary cancer (four of eight patients,
50.0 %).
Discussion
In this study, patients with various solid tumor types were
screened, with enrollment consisting mainly of patients with
Table 3 Adverse events of interest
Dose 50 mg/m2 (n=7) 100 mg/m2 (n=3) 200 mg/m2 (n=7) Total (n=17)
Grades 1 2 3 1 2 3 1 2 3 1 2 3 n (%)
Total 0 1 1 1 0 0 1 1 0 2 2 1 5 (29.4)
Cytokine release syndrome 0 1 1 0 0 0 0 1 0 0 2 1 3 (17.6)
Hot flush 1 0 0 1 0 0 0 0 0 2 0 0 2 (11.8)
Pyrexia 1 0 0 0 0 0 1 0 0 2 0 0 2 (11.8)
Arthralgia 1 0 0 0 0 0 0 0 0 1 0 0 1 (5.9)
Flushing 0 0 0 0 0 0 1 0 0 1 0 0 1 (5.9)
Nausea 0 0 0 0 0 0 1 0 0 1 0 0 1 (5.9)
Fig. 1 Serum concentration of amatuximab in cycle 1. n=7 in 50 and
200 mg/m2, n=3 in 100 mg/m2 dose group on cycle 1 day 1. n=5 in
50 mg/m2, n=3 in 100 mg/m2, n=6 in 200 mg/m2 dose group on cycle
1 day 22. Error bars show standard deviation. Abbreviations: SD=
standard deviation
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colorectal cancer and pancreatic adenocarcinoma. The MTD
was determined to be 200 mg/m2. A higher dose than 200 mg/
m2 was not investigated in this study because 400 mg/m2 was
judged as intolerable due to two DLTs (elevation of ALT/AST
and serum sickness) in the previous US phase I study [13].
The most common treatment-related AEs were fatigue
and pyrexia, which were grade 1 and easily managed. The
grade 3 or higher treatment-related AEs were cytokine
release syndrome (grade 3) and ILD (grade 5), which
occurred in one patient each. There were no apparent
dose-related trends in frequency or severity of treatment-
related AEs. Five patients experienced AEIs; however, all
AEIs were manageable. These findings are consistent with
the US phase I single agent amatuximab study [13]. Two
patients experienced DLTs in this study (cytokine release
syndrome and ILD each), whereas three patients experi-
enced DLTs in the US phase I study (deep venous throm-
bosis at 100 mg/m2, elevation of ALT/AST and serum
sickness at 400 mg/m2). In this study, a grade 2 AST
increased was observed in two patients; moreover, events
of grade 2 and 3 cytokine release syndrome were ob-
served in two patients and one patient, respectively.
The first DLT involving grade 3 cytokine release syndrome
occurred during the fourth infusion of amatuximab (on day
22) in the first patient at the 50 mg/m2 dose level. No
premedication to prevent allergic reaction were administered
to this patient. The patient experienced symptoms, including
dyspnea, within minutes after starting the amatuximab infu-
sion. All symptoms were resolved by stopping the infusion.
The amatuximab infusion was resumed at a lower rate
(1 mg/min); however, dyspnea, chills, and shivering subse-
quently appeared with marked wet rales of lung. Consequent-
ly, the amatuximab infusion was discontinued. These symp-
toms disappeared rapidly with antihistamines and corticoste-
roid administration, and this event of cytokine release syn-
drome was resolved on the following day (day 23). Hypoten-
sion did not occur with this adverse event. No subsequent
amatuximab infusions were administered to this patient, who
was then withdrawn from the study. Because grade 2 cytokine
release syndrome with chill and shivering also occurred in a
fourth patient at the 50 mg/m2 dose level, the study protocol
was amended to make premedication of antihistamines and
acetaminophen mandatory. After the protocol amendment, no
AEI of grade 3 or higher occurred and the frequency of AEIs
decreased. Consequently, premedication would be required in
the next phase study as well.
The secondDLTwas a grade 5 ILD in a patient with pleural
mesothelioma. After the fourth infusion of amatuximab (final
Table 4 Pharmacokinetic parameters
Parameter Dose
50 mg/m2 100 mg/m2 200 mg/m2
Day 1 n=7 n=3 n=7
Cmax (μg/mL)
† 33.2±3.57 65.1±4.76 133±19.2
tmax (h)
‡ 1.73 (0.72–2.72) 1.42 (1.00–1.58) 2.87 (1.52–5.68)
AUC(0–24) (μg•h/mL)
† 589±49.6 1270±125 2370±403
AUC(0-t) (μg•h/mL)
† 2380±318 5710±615 10300±2230
AUC(0-inf) (μg•h/mL)
† 3430±778 8540±588 15800±3440
t1/2 (h)
† 92.3±14.4 104±24.9 108±17.9
CL (mL/h/m2)† 15.2±2.98 11.8±0.833 13.3±3.46
Vss (L/m
2)† 1.99±0.183 1.77±0.346 2.06±0.465
Day 22 n=5 n=3 n=6
Cmax (μg/mL)
† 40.4±6.51 86.1±23.4 163±33.2
tmax (h)
‡ 1.270 (0.80–2.28) 2.620 (2.53–2.62) 1.295 (1.12–1.82)
AUC(0–24) (μg•h/mL)
† 774±184 1650±516 3110±900
AUC(0-t) (μg•h/mL)
† 3210±1360 8070±2980 15500±6610
t1/2 (h)
† 101±60.9 134±35.9 154±98.3
†mean±standard deviation
‡median (min–max)
AUC area under the serum concentration-time curve; AUC(0–24)AUC from zero to 24 h; AUC(0-t)AUC from zero to the time of last observation; AUC(0-
inf) AUC from zero to infinity; Cmax maximum serum concentration; CL total clearance; t1/2 terminal half-life; tmax time at which the highest serum drug
concentration occurs; Vss distribution volume at steady state
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infusion in the patient) on day 22, a grade 2 ILD occurred on
day 27, complicated by a grade 3 pneumonia with no causal
relationship to amatuximab. Although the symptoms of pneu-
monia were improved by the antibacterial agent on day 33, the
patient died due to the ILD on day 60. Considering the time
course from amatuximab infusion to the onset of the event, a
causal relationship with amatuximab infusion could not be
ruled out with certainty; therefore, it was considered to be
probably related. Given the clinical findings, the direct cause
of death appeared to be respiratory failure due to aggravation
of interstitial pneumonia rather than the underlying pleural
mesothelioma. Although no other patients experienced AEs
related to ILD in either this study or the US phase I study [13],
careful attention should be paid to ILD.
Pharmacokinetic analysis revealed that amatuximab exhib-
ited a biphasic distribution and was gradually eliminated. The
pharmacokinetic profile of amatuximab was characterized by
low clearance and a low distribution volume, which is similar
to the pharmacokinetic profiles exhibited by other anti-
receptor antibodies [15]. Fig. 3 shows the relationship
Fig. 2 Individual serum concentrations in cycle 1. (a) 50 mg/m2 dose
group (n=7). (b) 100 mg/m2 dose group (n=3). (c) 200 mg/m2 dose
group (n=7). Red line: HACA-positive patients who showed a decrease
in the serum concentration in cycle 1
Table 5 Mesothelin expression by immunohistochemistry
Tumour type No. of patients† %
Mesothelioma 2/2 100.0
Head and neck cancer 2/2 100.0
Small intestinal cancer 1/1 100.0
Pancreatic adenocarcinoma 4/5 80.0
Colorectal cancer 10/19 52.6
Biliary cancer 4/8 50.0
Non-small cell lung cancer 1/4 25.0
Other tumour types‡ 0/12 0.0
Total 24/53 45.3
† Number of patients mesothelin positive / number of patients evaluable
for mesothelin expression
‡Other tumour types; gastric cancer, small cell lung cancer, sarcoma (two
patients, each), orbital abscess, carcinoma of unknown primary, anal
cancer, melanoma, esophageal cancer, phyllodes tumour (one patient,
each)
Fig. 3 Relationship between dose and pharmacokinetic parameters of
Cmax and AUC(0–24) on cycle 1 day 1. (a) Cmax. (b) AUC(0–24).
Abbreviations: AUC=area under the concentration curve; AUC(0–24)=
AUC from zero to 24 h; Cmax=maximum serum concentration; JP=
Japan; US=United States
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between dose and the pharmacokinetic parameters of Cmax
and AUC(0–24) on cycle 1 day 1. The results demonstrate that
the Cmax and AUC values increased in an almost dose-
proportional manner within a dose range of 50 to 200 mg/m2.
In addition, these data show that the pharmacokinetic profile of
amatuximab in Japanese patients is similar to that in the US
patients.
In this study, eight of 17 treated patients (47.1 %) developed
HACA. The frequency of patients developing HACA-positivity
in this study is high as compared to seven of 24 treated patients
(29.2 %) in the US phase I study [13]. However, the occurrence
of HACA in this study dropped to 30.8 % (four of 13 patients
with premedication) as compared to 100.0 % (four of four
patients without premedication). Furthermore, the four HACA-
positive patients with premedication included one patient whose
HACA titer level was low and two patients who developed
HACA at the final sampling point after finishing study treatment
and premedications. This means that only one of the 13 patients
developed HACAwith high titer levels during the premedication
treatment period. Thus, premedication tends to decrease expres-
sion of HACA, although the mechanism behind how the HACA
expression is controlled by premedication of antihistamines and
acetaminophen is unknown.
Although there was no objective tumor response to
amatuximab, three patients (17.6 %) experienced SD, most of
whom had been heavily pre-treated. There were two colorectal
cancer patients and one pancreatic adenocarcinoma patient with
periods of durable SD by amatuximab monotherapy, but the
numbers were too small to be meaningful. Results of a single
arm phase II study in patients with pleural mesothelioma indicate
that a median overall survival of 14.8 months with a third of the
patients alive at the time of analysis is suggestive of antitumor
activity arising from the combination of amatuximab plus
pemetrexed/cisplatin [16]. A randomized, placebo-controlled
study is planned to investigate the survival benefit of this
combination.
Mesothelin expression was observed by IHC in multiple
patients with mesothelioma, head and neck, pancreatic adeno-
carcinoma, colorectal cancer, and biliary cancer. The frequen-
cies of patients with mesothelin expression were high in
mesothelioma and pancreatic adenocarcinoma, consistent
with prior reports [6–8]. The relationship between efficacy
and mesothelin expression is unclear, since apparent tumor
regression could not be observed in this study. However,
considering the mode of action by amatuximab, colorectal
cancer and biliary cancer, which were frequently reported to
be mesothelin positive in this study, can be potential targets in
the future clinical development of amatuximab. As a predic-
tive biomarker for amatuximab response was not identified in
this study, further biomarker research including mesothelin
expression should be done in future clinical study.
In conclusion, the MTD of this study was determined to be
200mg/m2. However, the actualMTD of amatuximabmight be
higher than 200mg/m2, since dosing above 200mg/m2 was not
investigated in this study. Amatuximab was generally well
tolerated at the 50, 100, or 200 mg/m2 dose level in patients
with solid tumors. Although there were no objective responses,
disease stabilization was observed in some patients. The effi-
cacy of amatuximab in combination with cytotoxic drugs is to
be investigated in other studies. Amatuximab exhibited a bi-
phasic distribution and was gradually eliminated. The Cmax and
AUC values on cycle 1 day 1 increased in an almost dose-
proportional manner within a dose range of 50 to 200mg/m2. In
addition, the pharmacokinetic profile of amatuximab in Japa-
nese patients is similar to that in the US patients.
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